In the second instalment of our blog series on new government policy, Lewis Miles and Linda Bedenik examine the UK's Trade and National Security strategies and what they mean for biotech.
In this blog, Abby Clark builds on a round table the BIA hosted with Chi Onwurah MP and Newcastle life science companies to explore the landscape and the drivers which make the sector strong, yet undervalued.
In this blog, Martin Turner, Director of Policy and External Affairs at BIA, reflects on the long-anticipated Life Sciences Sector Plan and what it means for scaling UK biotech. This is the first in a series of blogs that will be released in the coming weeks.
In this blog, Paul Wann, Business Director Sustainability & Decarbonisation, Emerson, discusses how life sciences companies can reduce emissions and improve sustainability through advanced automation, process control, and efficient management of utilities without compromising the quality or availability of vital therapies.
In this blog, Dr Jonathan Tobin, Partner, Brandon Capital, explores how the UK pension industry can unlock greater economic and societal value by following Australia's example.
MSD's record-breaking $10 billion acquisition of Verona Pharma illustrates the potential of our sector, but also is a reminder of the need to strengthen UK capital markets.
In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares the vision of hope witnessed at BIA's recent TechBio X event in Cambridge.
In this blog, Sarah Potter, Partner - Patent Attorney and Robert Cogger-Ward, Associate at Potter Clarkson, share what you need to know about DSI and the Cali Fund.
In this latest white paper, Dave Cooper, Project Pursuit Manager at Emerson, explores how forward-thinking biotech companies can meet the growing demand for personalised treatments by reimagining their manufacturing strategies.
Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment; Initial proof-of-concept data expected in second half of 2026
Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.
Medicines Discovery Catapult's Chemical Protein Stability Assay generates vital data to support drug discovery innovators and will enhance Selvita’s screening platform.
The policy landscape for deep biotech has seen remarkable strides over the past year, positioning the UK as a leader in engineering biology innovation.
In 2035, we envision a UK biotech sector with a stronger long-term capital base supporting both early—and later-stage firms. To make Vision 2035 a reality, we, as a sector, must focus on areas that will have the greatest impact. Read the report to find out what those are!
Watch the recording to see how the BIA Regulatory and Access Community is driving UK life sciences forward through expert insights on ILAP, MHRA initiatives, and collaborative innovation.
